An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study
Sponsor: CytoDyn, Inc.
Terminated
FDA required the sponsor to halt enrollment in the trial and transition participants to available therapies for the treatment of their disease. The trial was subsequently terminated once participants were transitioned.
Other terminated trials from CytoDyn, Inc.
More terminations from CytoDyn, Inc.
Listed as NCT02990858, this PHASE2/PHASE3 trial focuses on Human Immunodeficiency Virus (HIV) and remains terminated or withdrawn. Sponsored by CytoDyn, Inc., it has been updated 9 times since 2016, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE2/PHASE3
Status: Unknown → Terminated
-
Sep 2024 — Dec 2025 [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
Status: Active Not Recruiting → Unknown Status
-
Nov 2021 — Oct 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Unknown Status → Active Not Recruiting
▶ Show 4 earlier versions
-
Jan 2021 — Nov 2021 [monthly]
Unknown Status PHASE2_PHASE3
Status: Enrolling By Invitation → Unknown Status
-
Jun 2018 — Jan 2021 [monthly]
Enrolling By Invitation PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Enrolling By Invitation PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE2_PHASE3
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CytoDyn, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.